Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2015; 61(1): 102-111



    Khmelnytsky Regional Hospital


Endothelial dysfunction is implicated in the pathogenesis of diabetes and atherosclerosis. Endothelial monocyte-activating polypeptide-II (EMAP-II) is a multifunctional polypeptide with proinflammatory and antiangiogenic activity. EMAP-II induces procoagulant activity on the surface of endothelial cells, increases expression of E- and P-selectins and tumor necrosis factor-1, directs migration of monocytes and neutrophils, induces apoptosis in endothelial cells. The mechanisms of effects on endothelial cells, inflammatory action, anti-tumor properties, pathogenic role in diseases of the central nervous system involved in the development of the lungs during embryogenesis and pathogenic role in diseases of the lungs, in the development of cardiovascular disease.

Keywords: EMAP-II, endothelial dysfunction.


  1. Kao J, Ryan J, Brett G, Chen J, Shen H, Fan YG, Godman G, Familletti PC, Wang F, Pan YC. Endothelial monocyteactivating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem. 1992 Oct 5;267(28):20239-47.
  3. Shalak V, Kaminska M, Mitnacht-Kraus R, Vandenabeele P, Clauss M, Mirande M. The EMAPII cytokine is released from the mammalian multisynthetase complex after cleavage of its p43/proEMAPII component. J Biol Chem. 2001 Jun 29;276(26):23769-76.
  5. Han JM, Park SG, Lee Y, Kim S. Structural separation of different extracellular activities in aminoacyl-tRNA synthetase-interacting multi-functional protein, p43/ AIMP1. Biochem Biophys Res Commun. 2006 Mar 31;342(1):113-8.
  7. Norcum MT, Warrington JA. The cytokine portion of p43 occupies a central position within the eukaryotic multisynthetase complex. J Biol Chem. 2000 Jun 16;275(24):17921-4
  9. Kao J, Houck K, Fan Y, Haehnel I, Libutti SK, Kayton ML, Grikscheit T, Chabot J, Nowygrod R, Greenberg S. Characterization of a novel tumor-derived cytokine. Endothelial monocyte activating polypeptide II. J Biol Chem. 1994 Oct 7;269(40):25106-19.
  11. Savytskyi OV, Yesylevskyy SO, Kornelyuk AI. Asymmetric structure and domain binding interfaces of human tyrosyl-tRNA synthetase studied by molecular dynamics simulations. J Mol Recognit. 2013 Feb;26(2):113-20.
  13. Kondratiuk I, Khoruzenko A, Cherednyk O, Filonenko V, Kornelyuk A. Monoclonal antibodies against tyrosyltRNA synthetase and its isolated cytokine-like domain. Monoclon Antib Immunodiagn Immunother. 2013 Jun;32(3):200-4.
  15. Kwon HS, Park MC, Kim DG, Cho K, Park YW, Han JM, Kim S. Identification of CD23 as a functional receptor for the proinflammatory cytokine AIMP1/p43. J Cell Sci. 2012 Oct 1;125(Pt 19):4620-9.
  17. Lee SW, Cho BH, Park SG, Kim S. Aminoacyl-tRNA synthetase complexes: beyond translation. J Cell Sci. 2004 Aug 1;117(Pt 17):3725-34.
  19. Ko YG, Park H, Kim T, Lee JW, Park SG, Seol W, Kim JE, Lee WH, Kim SH, Park JE, Kim S. A cofactor of tRNA synthetase, p43, is secreted to upregulate proinflammatory genes. J Biol Chem. 2001 Jun 22;276(25):23028-33.
  21. Chang SY, Ko HJ, Heo TH, Kang CY. Heparan sulfate regulates the antiangiogenic activity of endothelial monocyte-activating polypeptide-II at acidic pH. Mol Pharmacol. 2005 May;67(5):1534-43.
  23. Yao C, Williams AJ, Ottens AK, Lu XC, Liu MC, Hayes RL, Wang KK, Tortella FC, Dave JR. P43/pro-EMAPII: a potential biomarker for discriminating traumatic versus ischemic brain injury. J Neurotrauma. 2009 Aug;26(8):1295-305.
  25. Kao J, Fan YG, Haehnel I, Brett J, Greenberg S, Clauss M, Kayton M, Houck K, Kisiel W, Seljelid R. A peptide derived from the amino terminus of endothelial-monocyteactivating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. J Biol Chem. 1994 Apr 1;269(13):9774-82.
  27. Chen Y, Legan SK, Mahan A, Thornton J, Xu H, Schwarz MA. Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiation. Respir Res. 2012 Jan 3;13:1.
  29. Daemen MA, van 't Veer C, Denecker G, Heemskerk VH, Wolfs TG,Clauss M. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest. 1999 Sep;104(5):541-9.
  31. Clarijs R, Schalkwijk L, Ruiter DJ, deWaal RM. EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2003 May;44(5):1801-6.
  33. Murray JC, Heng YM, Symonds P, Rice K, Ward W, Huggins M, Todd I, Robins RA. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis. J Leukoc Biol. 2004 May;75(5): 772-6.
  35. Berger AC, Alexander HR, Wu PC, Tang G, Gnant MF, Mixon A, Turner ES, Libutti SK. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte-activating polypeptide II (EMAPII). Cytokine. 2000 Jul;12(7): 992-1000.
  37. Van Horssen R, ten Hagen TLM, Eggermont AMM. TNF  in cancer treatment: Molecular insights, antitumor effects and clinical utility. Oncologist. 2006 Apr;11(4):397-408.
  39. Marvin MR1, Libutti SK, Kayton M, Kao J, Hayward J, Grikscheit T, Fan Y, Brett J, Weinberg A, Nowygrod R, LoGerfo P, Feind C, Hansen KS, Schwartz M, Stern D, Chabot J. A novel tumor-derived mediator that sensitizes cytokineresistant tumors to tumor necrosis factor. J Surg Res. 1996 Jun;63(1):248-55.
  41. Wu PC, Alexander HR, Huang J, Hwu P, Gnant M, Berger AC, Turner E, Wilson O, Libutti SK. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)- alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res. 1999 Jan 1;59(1):205-12.
  43. Crippa L, Gasparri A, Sacchi A, Ferrero E, Curnis F, Corti A. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha. Cancer Res. 2008 Feb 15;68(4):1154-61.
  45. Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple intransit metastases. Ann Surg. 2004 Dec;240(6):939-47.
  47. van Horssen R, Rens JA, Brunstein F, Guns V, van Gils M, Hagen TL, Eggermont AM. Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion. Int J Cancer. 2006 Sep 15;119(6):1481-90.
  49. Yamamoto M, Fukushima T, Ueno Y, Hayashi S, Kimura H, Soma G, Tomonaga M. Clinical significance of the expression of endothelial-monocyte activating polypeptide II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor necrosis factor-alpha (TNFSAM2). Anticancer Res. 2000 NovDec;20(6A):4081-6.
  51. Schwarz RE, Schwarz MA. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II. J Surg Res. 2004 Jul;120(1): 64-72.
  53. Liu J, Liu L, Xue Y, Meng F, Li S, Wang P, Liu Y. Antineoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells. Biochem Pharmacol. 2014 Jun 15;89(4):477-89.
  55. Reznikov OH, Chaĭkovs'ka LV, Poliakova LI, Sachyns'ka OV. Effects of cytokine-like polypeptide EMAP II and flutamide on the testosterone-stimulated prostate of castrated rats. Fiziol Zh. 2011;57(4):12-20.
  57. Reznikov AG, Chaykovskaya LV, Polyakova LI, Kornelyuk AI, Grygorenko VN. Cooperative antitumor effect of endothelial-monocyte activating polypeptide II and flutamide on human prostate cancer xenografts. Exp Oncol. 2011 Dec;33(4):231-4.
  59. Reznikov AG, Chaykovskaya LV, Polyakova LI, Kornelyuk AI. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model. Exp Oncol. 2007 Dec;29(4):267-71.
  61. Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. J Exp Clin Cancer Res. 2013 Mar 6;32:12.
  63. Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. PLoS One. 2012;7(6):e38477.
  65. Stathaki M, Armakolas A, Dimakakos A, Kaklamanis L, Vlachos I, Konstantoulakis MM, Zografos G, Koutsilieris M. Kisspeptin effect on endothelial monocyte activating polypeptide II (EMAP-II)-associated lymphocyte cell death and metastases in colorectal cancer patients. Mol Med. 2014 Mar 18;20:80-92.
  67. Li Z, Liu YH, Xue YX, Liu LB, Xie H. Mechanisms for endothelial monocyte-activating polypeptide-II-induced opening of the blood-tumor barrier. J Mol Neurosci. 2012 Jun;47(2):408-17.
  69. Li Z, Liu YH, Xue YX, Liu LB, Wang P. Signal mechanisms underlying low-dose endothelial monocyteactivating polypeptide-II-induced opening of the bloodtumor barrier. J Mol Neurosci. 2012 Sep;48(1):291-301.
  71. Li Z, Liu YH, Xue YX, Liu LB, Wang P. Low-dose endothelial monocyte-activating polypeptide-ii increases permeability of blood-tumor barrier by caveolaemediated transcellular pathway. J Mol Neurosci. 2014 Mar;52(3):313-22.
  73. Sen E, Ulger F, Kaya A, Akar N, Gonullu U. Serum endothelial monocyte-activating polypeptide-II: a novel biomarker in patients with non-small-cell lung cancer. Clin Lung Cancer. 2008 May;9(3):166-70.
  75. van Horssen R, Rens JA, Schipper D, Eggermont AM, ten Hagen TL. EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization. Apoptosis. 2006 Dec;11(12):2137-45.
  77. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000 Aug 1;60(15):4066-9.
  79. Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab Invest. 2009 Jan;89(1):38-46.
  81. Tandle AT, Calvani M, Uranchimeg B, Zahavi D, Melillo G, Libutti SK. Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome. Exp Cell Res. 2009 Jul 1;315(11):1850-9.
  83. Park SG, Kang YS, Ahn YH, Lee SH, Kim KR, Kim KW, Koh GY, Ko YG, Kim S. Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis. J Biol Chem. 2002 Nov 22; 277(47): 45243-8.
  85. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992 Mar;140(3): 539-44.
  87. Mueller CA, Schluesener HJ, Conrad S, Meyermann R, Schwab JM. Spinal cord injury induces lesional expression of the proinflammatory and antiangiogenic cytokine EMAP II. J Neurotrauma. 2003 Oct;20(10):1007-15.
  89. Mueller CA, Richt JA, Meyermann R, Deininger M, Schluesener H. Accumulation of the proinflammatory cytokine endothelial-monocyte-activating polypeptide II in ramified microglial cells in brains of Borna virus infected Lewis rats. Neurosci Lett. 2003 Mar 27;339(3):215-8.
  91. Zhang Z, Zhang Z, Artelt M, Burnet M, Schluesener HJ. Dexamethasone attenuates early expression of three molecules associated with microglia/macrophages activation following rat traumatic brain injury. Acta Neuropathol. 2007 Jun;113(6): 675-82.
  93. Liao Y, Zhang Z., Liu J., Schluesener H.J., Zhang Z., Wu Y. Lesional expression of EMAPII in macrophages/ microglia following cerebral ischemia in rats. Int J Neurosci. 2011 Feb;121(2):58-64.
  95. Warburton D, Schwarz M, Tefft D, Flores-Delgado G, Anderson KD, Cardoso WV. The molecular basis of lung morphogenesis. Mech Dev. 2000 Mar 15;92(1): 55-81.
  97. Journeay WS, Janardhan KS, Singh B. Expression and function of endothelial monocyte-activating polypeptideII in acute lung inflammation. Inflamm Res. 2007 May;56(5):175-81.
  99. Clauss M, Voswinckel R, Rajashekhar G, Sigua NL, Fehrenbach H, Rush NI, Schweitzer KS, Yildirim AÖ, Kamocki K, Fisher AJ, Gu Y, Safadi B, Nikam S, Hubbard WC, Tuder RM, Twigg HL, Presson RG, Sethi S, Petrache I. Lung endothelial monocyte-activating protein 2 is a mediator of cigarette smoke-induced emphysema in mice. J Clin Invest. 2011 Jun;121(6): 2470-9.
  101. Green LA, Petrusca D, Rajashekhar G, Gianaris T, Schweitzer KS, Wang L, Justice MJ, Petrache I, Clauss M. Cigarette smoke-induced CXCR3 receptor up-regulation mediates endothelial apoptosis. Am J Respir Cell Mol Biol. 2012 Dec;47(6):807-14.
  103. Lal CV, Schwarz MA. Vascular mediators in chronic lung disease of infancy: role of endothelial monocyte activating polypeptide II (EMAP II). Birth Defects Res A Clin Mol Teratol. 2014 Mar;100(3):180-8.
  105. Green LA, YiR, Petrusca D, Wang T, Elghouche A, Gupta SK, Petrache I, Clauss M. HIV envelope protein gp120- induced apoptosis in lung microvascular endothelial cells by concerted upregulation of EMAP II and its receptor, CXCR3. Am J Physiol Lung Cell Mol Physiol. 2014 Feb 15;306(4):L372-82.
  107. Zheng M, Schwarz MA, Lee S, Kumaraguru U, Rouse BT. Control of stromal keratitis by inhibition of neovascularization. Am J Pathol. 2001 Sep;159(3):1021-9.
  109. Liu SH, Gottsch JD. Apoptosis induced by a cornealendotheliumderived cytokine. Invest Ophthalmol Vis Sci. 1999 Dec;40(13):3152-9.
  111. Nomura S, Ishii K, Shimizu M, Inami N, Uoshima N, Urase F, Maeda Y, Hayashi K. The significance of EMAPII after allogeneic stem cell transplantation. Transpl Immunol. 2009 May;21(1):23-6.
  113. Wellings RP, Lash GE, Murray JC, Tas M, Ward W, Trew AJ, Baker PN. Endothelial monocyte-activating polypeptide-2 is increased in pregnancy but is not further increased in preeclampsia. J Soc Gynecol Investig. 1999 May-Jun;6(3):142-6.
  115. Battersby S, Boddy SC, Critchley HO, Jabbour HN. Expression and localization of endothelial monocyteactivating polypeptide II in the human endometrium across the menstrual cycle: regulation of expression by prostaglandin E(2). J Clin Endocrinol Metab. 2002 Aug;87(8):3928-35.
  117. Mishchuk VV, Pyptiuk OV. Diagnostic significance of some indices of systemic inflammation in peritonitis. Klin Khir. 2010 Jan;(1):36-9.
  119. Liu D, Wise GE. Expression of endothelial monocyteactivating polypeptide II in the rat dental follicle and its potential role in tooth eruption. Eur J Oral Sci. 2008 Aug;116(4):334-40.
  121. Martinet W, De Meyer I, Cools N, Timmerman V, Bult H, Bosmans J, De Meyer GR. Cell death-mediated cleavage of the attraction signal p43 in human atherosclerosis: implications for plaque destabilization. Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1415-22.
  123. Nührenberg TG, Voisard R, Fahlisch F, Rudelius M, Braun J, Gschwend J, Kountides M, Herter T, Baur R, Hombach V, Baeuerle PA, Zohlnhöfer D. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J. 2005 Feb;19(2):246-8.
  125. Zohlnhöfer D, Nührenberg TG, Neumann FJ, Richter T, May AE, Schmidt R, Denker K, Clauss MA, Schömig A, Baeuerle PA. Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. Mol Pharmacol. 2004 Apr;65(4):880-9.
  127. Nührenberg TG, Langwieser N, Schwarz JB, Hou Y, Frank P, Sorge F, Matschurat S, Seidl S, Kastrati A, Schömig A, Clauss MA, Zohlnhöfer D. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. Cardiovasc Res. 2008 Feb 1;77(3):580-9.
  129. Keezer SM, Ivie SE, Krutzsch HC, Tandle A, Libutti SK, Roberts DD. Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res. 2003 Oct 1;63(19):6405-12.
  130. Schwarz MA, Zheng H., Liu J, Corbett S, Schwarz RE. Endothelial monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin. Exp Cell Res. 2005 Dec 10;311(2):229-39.
  132. Lylo VV, Matsevich LL, Kotsarenko EV, Babenko LA, Korneliuk AI, Sukhorada EM, Lukash LL. Induction of repair enzyme O6-methylguanine-DNA methyltransferase gene expression under the influence of  cytokine EMAP II in human cells in vitro. Tsitol Genet. 2011 Nov-Dec;45(6):53-60.
  134. Schwarz MA, Thornton J, Xu H, Awasthi N, Schwarz RE. Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide II. PLoS One. 2012;7(3): e33101.
  136. Hou Y, Plett PA, Ingram DA, Orschell CM, Yoder MC. Endothelial monocyte-activating polypeptide-II induces migration of endothelial progenitor cells via the chemokine receptor CXCR3. Exp Hematol. 2006 Aug;34(8):1125-32.
  138. Thompson JL, Ryan JA, Barr ML, Franc B, Starnes VA, Schwarz MA. Potential role for antiangiogenic proteins in the myocardial infarction repair process. J Surg Res. 2004 Jan;116(1):156-64.
  140. Tsai BM, Wang M, Clauss M, Sun P, Meldrum DR. Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine. Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R767-71.
  142. Rajashekhar G, Mitnacht-Kraus R, Ispe U, Garrison J, Hou Y, Taylor B, Petrache I, Vestweber D, Clauss M. A monoclonal rat anti-mouse EMAP II antibody that functionally neutralizes pro- and mature-EMAP II in vitro. J Immunol Methods. 2009 Oct 31;350(1-2):22-8.
  144. Journeay S, Singh B. EMAP-II antibody detects both proEMAP/p43 and mature EMAP-II molecules. Acta Neuropathol. 2007 Oct;114(4):435.

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.